| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Agrippressin (arginine vasopressin, AVP) acts on V₁, V₂, and V₃ vasopressin receptors. V₁ receptors (Gq protein-coupled) mediate vasoconstriction, platelet aggregation, and glycogenolysis. V₂ receptors (Gs protein-coupled) mediate antidiuretic effects via aquaporin-2 insertion and release of von Willebrand factor and factor VIII. V₃ receptors mediate adrenocorticotropic hormone (ACTH) secretion. [3]
|
|---|---|
| ln Vitro |
Arbopressin binds to A7r5 arterial aortic smooth muscle cells via vasopressin uptake V1, with a Kd of 1.31 nM. Additionally, it promotes immunological response against S-100 in non-cultured DRG cells, AVP-induced [Ca2+]i signaling, and intracellular calcium release in A7r5 cells (EC50=5 nM) [1]. The lowest effective dose of argipressin required to elicit a [Ca2+]i response in DRG cultured neuronal cells is 100 pM[2].
|
| ln Vivo |
In patients with refractory septic shock, Agrippressin infusion at 2.4 U/h (0.04 U/min) increased systolic blood pressure from 92 to 146 mmHg and allowed withdrawal of catecholamine infusion, while urine output increased from 30 to 110 mL/h in three of five patients. [3]
In a randomized trial (VASST), low-dose AVP (0.01–0.03 U/min) plus norepinephrine in septic shock patients showed no difference in 28- or 90-day mortality overall, but in patients with less severe shock (baseline norepinephrine 5–15 μg/min), AVP reduced mortality by nearly 10% (26.5% vs. 35.7%, P < 0.05). [3] In post-cardiac surgery vasoplegic shock, AVP (0.01–0.03 U/min) was used to treat hypotension. A randomized trial (VANCS) of 330 patients showed that AVP as first-line therapy reduced the composite endpoint of mortality or severe complications (32% vs. 49% with norepinephrine, P = 0.001) and reduced atrial fibrillation (64% vs. 82%, P < 0.001). [3] In brain-dead organ donors, AVP infusion at 0.04–0.1 U/min normalized urine output, preserved renal function, and achieved hemodynamic stability with reduced catecholamine requirements. [3] In cardiopulmonary resuscitation, AVP (40 U IV bolus) was used as an alternative to epinephrine. A meta-analysis of six randomized controlled trials (n = 4,475) found no significant benefit or harm overall, but long-term survival benefit was observed in asystole patients. [3] In anaphylactic shock unresponsive to epinephrine, AVP has been successfully used. [3] |
| ADME/Pharmacokinetics |
Agrippressin (8-arginine vasopressin) must be given parenterally as it is hydrolyzed by trypsin. It is not protein-bound, with a volume of distribution of 140 mL/kg. The plasma half-life is 10–35 minutes. It is rapidly metabolized by liver and kidney vasopressinases (35%) and excreted through the kidney (65%). [3]
|
| Toxicity/Toxicokinetics |
Higher doses of Agrippressin may cause gastrointestinal and myocardial ischemia, reduced cardiac output via baroreceptor reflex, and reduced intestinal perfusion potentially leading to tissue necrosis and bacterial translocation. Cases of myocardial infarction and cardiac arrest have been reported after local intramyometrial infiltration. [3]
AVP activates V₂ receptors on endothelial cells, causing release of von Willebrand factor and enhancing platelet aggregation, increasing the risk of thrombosis. [3] Other adverse effects include hyponatremia, anaphylaxis, bronchospasm, urticaria, abdominal cramps, angina, and chest pain. [3] In sepsis, doses >0.04 U/min should be avoided as they may produce myocardial ischemia and cardiac arrest. [3] |
| References |
|
| Additional Infomation |
Argipressin is the major form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide with arginine at residue 8 and two disulfide-linked cysteine residues at residues 1 and 6. It has cardiovascular, hematologic, and mitogenic effects. It is the conjugate base of Argipressin (2+). Argipressin is a synthetic peptide, similar to the endogenous nonapeptide hormone, and possesses antidiuretic properties. Synthesized in the hypothalamus and stored in/released from the posterior pituitary gland, Argipressin's primary function is to regulate extracellular fluid volume. This substance can also act as a vasoconstrictor, increasing blood pressure and systemic vascular resistance. Argipressin is used to treat diabetes insipidus or to improve vasomotor tone and blood pressure.
Agrippressin (Pitressin, arginine vasopressin, AVP) is an endogenous nonapeptide hormone secreted by the posterior pituitary. It acts on V₁, V₂, and V₃ receptors. Its therapeutic uses include refractory septic shock, vasodilatory shock after cardiac surgery, intraoperative hypotension (especially in patients on renin-angiotensin system inhibitors), brain-dead organ donor management, cardiopulmonary resuscitation, and bleeding esophageal varices. The rationale for use in shock states is relative AVP deficiency and supersensitivity to exogenous AVP. Doses in shock typically range from 0.01 to 0.04 U/min by continuous infusion. [3] |
| Molecular Formula |
C46H65N15O12S2
|
|---|---|
| Molecular Weight |
1084.23
|
| Exact Mass |
1083.437
|
| CAS # |
113-79-1
|
| Related CAS # |
Argipressin diacetate;75499-44-4;Argipressin acetate;129979-57-3
|
| PubChem CID |
644077
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Flash Point |
113℃
|
| Index of Refraction |
1.724
|
| LogP |
-5.99
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
75
|
| Complexity |
2070
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1=CC=C(CC2NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(N)CSSCC(C(N3C(C(NC(C(NCC(N)=O)=O)CCC/N=C(\N)/N)=O)CCC3)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC2=O)C=C1
|
| InChi Key |
KBZOIRJILGZLEJ-LGYYRGKSSA-N
|
| InChi Code |
InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
|
| Chemical Name |
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
|
| Synonyms |
Vasopressin. H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond)Argpressin Acetate Pitressin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~92.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9223 mL | 4.6116 mL | 9.2231 mL | |
| 5 mM | 0.1845 mL | 0.9223 mL | 1.8446 mL | |
| 10 mM | 0.0922 mL | 0.4612 mL | 0.9223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
